Exact Sciences to Host Webcast and Conference Call Regarding U.S. Preventive Services Task Force Draft Recommendations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Exact Sciences (EXAS) Drops Another 20%
October 8, 2015 11:25 AM EDTExact Sciences (NASDAQ: EXAS) shares declined another 20% on Thursday, falling to under $8 per share.
Whitney Tilson Says Exact Sciences (EXAS) Still a Great Short
October 7, 2015 10:20 AM EDTHedge fund manager Whitney Tilson said Exact Sciences (NASDAQ: EXAS) is a great short at $10. Link
Mizuho Securities Cuts Price Target on Exact Sciences (EXAS) to $12 Following USPSTF Cologuard Guidelines
October 7, 2015 6:50 AM EDTMizuho Securities maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target on price target to $12.00 (from $35.00), after USPSTF Cologuard guidelines have hampered visibility and added risk. Cologuard was only listed as an alternative colorectal screening test for the average-risk... More
Exact Sciences (EXAS) PT Lowered to $15 at Roth Capital, Recommends Buying on Weakness
October 6, 2015 12:14 PM EDTRoth Capital analyst Chris Lewis lowered his price target on Exact Sciences (NASDAQ: EXAS) to $15.00 (from $31.00) after the USPSTF draft recommendation has designated Cologuard as an alternative rather than recommended test. The firm maintained a Buy rating ad is telling clients to buy on... More
Exact Sciences (EXAS) PT Slashed to $11 at Goldman Sachs on Negative USPSTF Ruling
October 6, 2015 9:32 AM EDTGoldman Sachs analyst Isaac Ro reiterated a Neutral rating and slashed his price target on Exact Sciences (NASDAQ: EXAS) to $11.00 (from $24.00) after the United States Preventative Services Task Force (USPSTF) issued a draft recommendation that included commentary that they view as negative... More
Canaccord Genuity Reiterates Buy on Exact Sciences (EXAS) Following USPSTF's Draft Recommendation for Colorectal Screening Guidelines
October 6, 2015 8:45 AM EDTCanaccord Genuity reiterated a Buy rating and $26.00 price target on Exact Sciences (NASDAQ: EXAS) following USPSTF's draft recommendation for colorectal screening guidelines. the report surprisingly did not include Cologuard as an "A" or "B" rated test, though it did mention it as an "alternative screening test" which EXAS interprets as being included in the... More
